Previous close | 1.1300 |
Open | 1.1000 |
Bid | 0.7920 x 200 |
Ask | 1.3900 x 200 |
Day's range | 1.0500 - 1.1300 |
52-week range | 0.8400 - 1.9300 |
Volume | |
Avg. volume | 69,622 |
Market cap | 45.441M |
Beta (5Y monthly) | 1.27 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.7600 |
Earnings date | 01 Apr 2024 - 10 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Quince Therapeutics and XBiotech are included in this Analyst Blog.
SOUTH SAN FRANCISCO, Calif., February 22, 2024--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, today announced the launch of a Scientific Advisory Board (SAB) comprised of leading experts in biochemistry, neurology, immunology, hematology, pharmacology, and clinical practice.
SOUTH SAN FRANCISCO, Calif., February 15, 2024--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, today announced the appointment of Rajiv Patni, M.D., a biopharma industry veteran and global product development expert, to the company’s Board of Directors.